MedPath

MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications

Not Applicable
Completed
Conditions
Open Angle Glaucoma
Registration Number
NCT03374553
Lead Sponsor
iSTAR Medical
Brief Summary

The study will evaluate the efficacy and safety of MINIject 636 and IOP lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery. Overall, the patient will be asked to perform several examinations up to 24 months after surgery.

The primary efficacy objective of the present study is to show the IOP reduction under medication 6 months after surgery compared to medicated diurnal IOP at screening.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • Diagnosis of primary or secondary open angle glaucoma during screening/baseline visit or earlier.
  • Grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to Shaffer Angle Grading System.
  • Glaucoma not adequately controlled
Exclusion Criteria
  • Diagnosis of glaucoma other than open angle glaucoma
  • Grade 2, grade 1 and grade 0 according to Shaffer Angle Grading System.
  • Neovascular glaucoma in the study eye
  • Prior glaucoma surgery in the study eye
  • Clinically significant corneal disease
  • Patients with poor vision

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Primary Outcome Measures
NameTimeMethod
Reduction in medicated diurnal IOP6 months after surgery

DODT/SODT arm will be evaluated separately

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Clínica Oftalmológica del Caribe

🇨🇴

Barranquilla, Colombia

Maxivision Eye Hospital

🇮🇳

Hyderabad, Telangana, India

Panama Eye Center

🇵🇦

Panama city, Panama

Clínica Oftalmológica del Caribe
🇨🇴Barranquilla, Colombia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.